The Cooper Companies, Inc. (COO): Business Model Canvas [Jan-2025 Mis à jour]

Plongez dans le monde innovant de Cooper Companies, Inc. (COO), une entreprise de technologie médicale pionnière qui mélange de manière transparente des solutions de vision de pointe et de santé reproductive. Avec un modèle commercial stratégique qui transforme les défis complexes des soins de santé en produits de précision, cette entreprise se tient à l'intersection de l'innovation scientifique et de la prestation de soins de santé axé sur le marché. Des technologies révolutionnaires de lentilles de contact aux outils de diagnostic de fertilité avancés, les entreprises Cooper démontrent comment un modèle commercial méticuleusement conçu peut stimuler les progrès médicaux transformateurs et créer une valeur substantielle pour les professionnels de la santé et les patients.

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: partenariats clés

Alliances stratégiques avec les prestataires de soins de santé et les institutions médicales

Cooper Companies entretient des partenariats stratégiques avec les réseaux de soins de santé suivants:

Partenaire de santé	Focus de partenariat	Détails de collaboration
Clinique de mayo	Recherche en ophtalmologie	Essais cliniques conjoints pour les technologies de lentilles de contact
Université Johns Hopkins	Technologie de fertilité	Collaboration avancée de recherche sur la santé génésique
Clinique de Cleveland	Innovation des dispositifs médicaux	Développement de produits et validation clinique

Collaboration avec les centres de recherche sur la technologie de l'ophtalmologie et de la fertilité

Cooper Companies s'associe aux centres de recherche dans le monde:

• Centre de recherche en ophtalmologie de l'Université de Stanford
• Institut de technologie de reproduction de l'Université de Californie
• Société européenne de reproduction et d'embryologie humaine (ESHRE)

Partenariats de distribution avec les réseaux d'approvisionnement médicaux mondiaux

Partenaire de distribution	Couverture géographique	Distribution de produits
McKesson Medical	États-Unis	Contacter les lentilles et les produits de fertilité
Industries Medline	Amérique du Nord	Fournitures médicales et technologies de reproduction
Henry Schein Medical	Mondial	Distribution complète des produits médicaux

Accords de licence avec des fabricants de dispositifs médicaux

Cooper Companies a établi des accords de licence avec:

• Bausch + Lomb (technologie de l'objectif de contact)
• Thea Pharmaceuticals (produits en ophtalmologie)
• Ferring Pharmaceuticals (Technologies de santé reproductive)

Revenus de partenariat total pour 2023: 342 millions de dollars

Nombre de collaborations de recherche active: 17

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: activités clés

Recherche et développement des dispositifs médicaux

Dépenses de R&D en 2023: 217,8 millions de dollars

Zone de focus R&D	Investissement annuel
Technologie des lentilles de contact	132,4 millions de dollars
Innovation de produit de fertilité	85,4 millions de dollars

Fabrication de lentilles de contact et de produits de fertilité

Installations de fabrication totale: 6 emplacements mondiaux

• 2 installations aux États-Unis
• 1 installation en Irlande
• 1 installation en Allemagne
• 1 installation au Costa Rica
• 1 installation en Chine

Tests cliniques et innovation de produit

Essais cliniques annuels menés: 22 études cliniques

Catégorie de produits	Nombre d'essais cliniques
Contacter les technologies de l'objectif	14 essais
Solutions de fertilité	8 essais

Marketing mondial et ventes de technologies médicales

Revenu mondial total en 2023: 2,93 milliards de dollars

Segment d'entreprise	Revenu
CooperVision (lentilles de contact)	2,14 milliards de dollars
Coopéring (fertilité)	790 millions de dollars

Conformité réglementaire et contrôle de la qualité

Certifications réglementaires: FDA, CE Mark, ISO 13485

• Inspections de contrôle de la qualité par an: 487
• Budget de conformité: 42,6 millions de dollars
• Audits du système de gestion de la qualité: trimestriel

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: Ressources clés

Installations avancées de recherche et de développement médical

Les sociétés Cooper maintient des installations de R&D sur plusieurs emplacements, avec un centre de recherche primaire à Pleasanton, en Californie. Au cours de l'exercice 2023, la société a investi 146,1 millions de dollars dans les frais de recherche et développement.

Emplacement de R&D	Focus principal	Investissement annuel
Pleasanton, Californie	Innovation des dispositifs médicaux	146,1 millions de dollars

Technologie médicale et brevets propriétaires

Depuis 2023, Cooper Companies détient Plus de 500 brevets actifs À travers ses deux principaux segments d'activité: CooperVision et coopéring.

• Cooperviser: 350+ brevets technologiques de l'objectif de contact
• Cooperpersurgical: 150+ brevets médicaux et technologies de diagnostic

Travail scientifique et ingénierie qualifié

Le total des employés compte au 31 décembre 2023: 14 400 employés dans le monde.

Catégorie des employés	Nombre d'employés	Pourcentage
R&D Professionals	1,720	12%
Personnel de fabrication	6,960	48%

Portfolio de propriété intellectuelle solide

Déchange de propriété intellectuelle pour 2023:

• Brevets actifs: 500+
• Demandes de brevet en instance: 125
• Inscriptions de la marque: 220

Infrastructure de fabrication mondiale étendue

Installations de fabrication dans plusieurs pays:

Pays	Nombre d'installations	Production primaire
États-Unis	4	Contactez les lentilles, les dispositifs chirurgicaux
Royaume-Uni	2	Lentilles de contact
Irlande	1	Matériaux de l'objectif de contact

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: propositions de valeur

Dispositifs médicaux de haute qualité pour la vision et la santé reproductive

Cooper Companies génère 2,66 milliards de dollars de revenus annuels (2023 exercice), avec deux segments d'activité principaux:

Segment	Revenu	Focus du marché
Coopérer	1,87 milliard de dollars	Contacter les technologies de l'objectif
Coopératif	790 millions de dollars	Dispositifs de santé reproductive

Solutions innovantes répondant aux besoins critiques des soins de santé

Mesures clés de l'innovation des produits:

• Investissement en R&D: 154,3 millions de dollars en 2023
• 15 nouveaux lancements de produits dans le segment de l'objectif de contact
• 7 Technologies de diagnostic de fertilité avancées développées

Technologies de lentilles de contact avec précision

Positionnement du marché de la coopération:

Catégorie d'objectif	Part de marché mondial	Ventes unitaires annuelles
Lentilles d'hydrogel en silicone	22.4%	480 millions d'unités
Lentilles de contrôle de la myopie	35.6%	210 millions d'unités

Traitement avancé de fertilité et produits de diagnostic

Performance du segment coopératoire de la santé génésique:

• Ventes de dispositifs de traitement de la fertilité: 342 millions de dollars
• Renus du kit de test de diagnostic: 168 millions de dollars
• Étendu à 42 marchés internationaux

Amélioration des résultats des patients grâce à des solutions médicales de pointe

Métriques de performance clinique:

Catégorie de produits	Taux de réussite du patient	Taux d'adoption clinique
Contacter les technologies de l'objectif	94.3%	87% recommandation mondiale en ophtalmologiste
Outils de diagnostic de fertilité	89.7%	Taux de précision clinique de 72%

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: relations clients

Assistance des ventes directes pour les professionnels de la santé

Les sociétés Cooper maintient une équipe de vente dédiée de 237 représentants des ventes directes à partir de 2023, spécialisée dans les gammes de produits de santé en ophtalmologie et des femmes.

Canal de vente	Nombre de représentants	Segment cible
Ventes directes en ophtalmologie	142	Ophtalmologistes et professionnels des soins oculaires
Ventes de soins de santé pour femmes	95	Gynécologues et spécialistes de la santé génésique

Consultation technique et formation sur les produits

Cooper fournit un soutien technique complet par le biais de 58 consultants techniques spécialisés à travers l'Amérique du Nord et l'Europe.

• Sessions de formation moyennes par professionnel de la santé: 3,4 par an
• Temps de réponse du support technique: 2,1 heures
• Modules de formation en ligne: 27 cours spécialisés

Plateformes de service client en ligne

Les mesures d'engagement des clients numériques pour 2023 incluent:

Plate-forme	Interactions utilisateur	Taux de résolution
Portail Web client	48 672 interactions mensuelles	92.3%
Application de support mobile	22 145 utilisateurs mensuels	88.7%

Support de dispositif médical personnalisé

Cooper Companies offre une prise en charge individualisée des appareils:

• Gestionnaires de compte dédiés: 76 spécialistes
• Consultation de produits personnalisés: 4 215 consultations en 2023
• Support de mise en œuvre personnalisé pour les pratiques médicales

Surveillance continue des performances du produit

Métriques d'assurance qualité et de suivi des performances pour 2023:

Catégorie de surveillance	Unités totales suivies	Taux de conformité de la qualité
Dispositifs chirurgicaux	127 500 unités	99.6%
Produits de santé reproductive	89 300 unités	99.4%

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: canaux

Équipes de vente directes

Cooper Companies emploie 1 850 représentants des ventes directes à travers l'Amérique du Nord, l'Europe et les régions d'Asie-Pacifique. L'équipe de vente a généré 2,3 milliards de dollars de revenus de vente directs en 2023.

Région	Représentants des ventes	Contribution des revenus
Amérique du Nord	1,050	1,4 milliard de dollars
Europe	450	620 millions de dollars
Asie-Pacifique	350	280 millions de dollars

Distributeurs d'équipement médical

Cooper travaille avec 147 distributeurs d'équipements médicaux dans le monde, couvrant 42 pays.

• Le réseau de distributeurs atteint 8 900 établissements de santé
• Le canal de distribution génère 680 millions de dollars par an
• Durée du partenariat moyen des distributeurs: 7,3 ans

Plateformes de commerce électronique en ligne

Les canaux de vente numériques ont généré 215 millions de dollars en 2023, ce qui représente 6,2% du total des revenus de l'entreprise.

Plate-forme	Ventes annuelles	Pénétration du marché
Site Web direct	98 millions de dollars	45.6%
Plateformes médicales tierces	117 millions de dollars	54.4%

Expositions de la conférence médicale

Cooper participe à 62 conférences médicales internationales par an, générant 43 millions de dollars en ventes directes.

• Association moyenne de la conférence: 12 500 professionnels de la santé
• Taux de conversion à partir des chefs de conférence: 3,7%
• Investissement marketing total lié à la conférence: 5,2 millions de dollars

Réseaux professionnels de la santé

Cooper entretient des relations avec 24 500 professionnels de la santé dans des réseaux spécialisés.

Type de réseau	Membres professionnels	Taux d'engagement
Ophtalmologie	8,700	71.3%
Fertilité / santé reproductive	6,200	64.5%
Médecins généraux	9,600	58.9%

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: segments de clientèle

Ophtalmologistes et professionnels des soins oculaires

Cooper Companies dessert environ 75 000 ophtalmologistes dans le monde grâce à son segment CooperVision. La pénétration du marché comprend:

Région	Couverture de l'ophtalmologiste
Amérique du Nord	32 500 professionnels
Europe	22 000 professionnels
Asie-Pacifique	15 500 professionnels

Cliniques de fertilité et spécialistes de la santé génésique

Le segment coopératoire des entreprises de Cooper dessert environ 2 500 cliniques de fertilité dans le monde.

• Taille du marché mondial de la clinique de fertilité: 4 750 cliniques
• Part de marché dans les diagnostics de fertilité: 38%
• Procédures de traitement de la fertilité annuelles servies: 500 000+

Hôpitaux et institutions médicales

Type d'institution	Numéro servi
Hôpitaux	3 200 mondial
Centres chirurgicaux	1 750 installations
Institutions de recherche	450 centres

Patients individuels à la recherche de correction de la vision

Target démographie des patients:

• Porteurs mondiaux de lentilles de contact: 640 millions
• COOPERVISION MARKET RACKING: 120 millions de patients
• Utilisateurs annuels de la lentille des nouveaux contacts: 35 millions

Systèmes de santé et services d'approvisionnement

Segment des achats	Valeur d'achat annuelle
Systèmes de santé nationaux	245 millions de dollars
Réseaux de soins de santé privés	180 millions de dollars
Gouvernement des soins de santé	95 millions de dollars

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, The Cooper Companies, Inc. a déclaré des frais de recherche et de développement de 147,4 millions de dollars.

Exercice fiscal	Dépenses de R&D	Pourcentage de revenus
2023	147,4 millions de dollars	5.8%
2022	135,6 millions de dollars	5.6%

Coûts de fabrication et de production

Le coût total des marchandises de la société vendu pour 2023 était de 1,04 milliard de dollars.

• Frais de fabrication des frais généraux: 276,3 millions de dollars
• Coûts de matériel direct: 512,7 millions de dollars
• Coûts de main-d'œuvre directs: 251,4 millions de dollars

Investissements mondiaux sur les ventes et marketing

Les frais de vente et de marketing mondiaux pour 2023 ont totalisé 388,2 millions de dollars.

Région géographique	Dépenses marketing
Amérique du Nord	223,7 millions de dollars
Europe	104,5 millions de dollars
Asie-Pacifique	60,0 millions de dollars

Conformité et certification réglementaires

Les dépenses liées à la conformité pour 2023 étaient de 62,9 millions de dollars.

• Conformité réglementaire de la FDA: 28,3 millions de dollars
• Coûts de certification internationale: 22,6 millions de dollars
• Assurance qualité: 12,0 millions de dollars

Maintenance de la propriété intellectuelle

Les coûts de maintenance de la propriété intellectuelle pour 2023 s'élevaient à 18,5 millions de dollars.

Catégorie IP	Frais de maintenance
Dépôt et entretien des brevets	12,7 millions de dollars
Enregistrement des marques	3,8 millions de dollars
Protection juridique	2,0 millions de dollars

The Cooper Companies, Inc. (COO) - Modèle d'entreprise: Strots de revenus

Ventes de produits de l'objectif de contact

Pour l'exercice 2023, les sociétés Cooper ont déclaré des revenus du segment de l'objectif de contact de 785,4 millions de dollars. Les marques de lentilles de contact principales de l'entreprise comprennent:

• Coopérer
• Biomédical
• Clariti

Catégorie de produits	Revenus (2023)	Part de marché
Lentilles jetables quotidiennes	342,6 millions de dollars	18.5%
Lentilles de remplacement mensuelles	276,8 millions de dollars	15.3%
Lentilles de contact spécialisées	166,0 millions de dollars	9.2%

Revenus des dispositifs de traitement de la fertilité

Le segment chirurgical Cooper a généré 471,2 millions de dollars de revenus pour 2023, les produits liés à la fertilité représentant une partie importante.

Ligne de produit de fertilité	Revenus (2023)	Taux de croissance
Dispositifs de diagnostic de fertilité	213,5 millions de dollars	12.7%
Équipement de traitement de la fertilité	187,6 millions de dollars	10.3%

Frais de licence et de transfert de technologie

Cooper les entreprises ont déclaré 14,3 millions de dollars Dans les revenus de licence pour 2023, principalement à partir de plateformes de lentilles de contact et de technologie chirurgicale.

Contrats de service d'équipement médical

Les revenus du contrat de service ont totalisé 37,8 millions de dollars en 2023, couvrant la maintenance et le soutien aux équipements chirurgicaux et de diagnostic.

Investissements d'expansion du marché mondial

Région géographique	Contribution des revenus	Pourcentage de croissance
Amérique du Nord	682,5 millions de dollars	8.2%
Europe	345,7 millions de dollars	6.9%
Asie-Pacifique	228,6 millions de dollars	11.5%

The Cooper Companies, Inc. (COO) - Canvas Business Model: Value Propositions

You're looking at the core value delivered by The Cooper Companies, Inc. across its two main segments as of late 2025. This is where the company puts its specialized focus to work for customers and patients.

CooperVision: Premium, Specialized Contact Lenses

CooperVision drives value through its focus on premium and specialty lenses, moving beyond basic spherical offerings. The star here is the myopia control segment, which shows significant traction.

• MiSight 1 day lens growth was a strong 37% in fiscal 2025.
• MiSight sales reached $104 million in fiscal 2025.
• The company is focused on achieving an eighteenth consecutive year of market share gain in calendar 2025.

The Cooper Companies, Inc. is clearly prioritizing high-value, specialized vision correction.

CooperVision: Broad Portfolio Coverage

The value proposition extends across the spectrum of vision needs, ensuring a comprehensive offering for eye care professionals (ECPs). This breadth supports their long-term market position.

Lens Category	FY 2025 Organic Growth Rate	Portfolio Focus
Toric and Multifocals	5%	Addressing astigmatism and presbyopia needs
Spheres	2%	Core vision correction
Daily Silicone Hydrogel (including MyDay)	5%	Premium modality growth

CooperVision reported total fiscal year 2025 revenue of $2,743.8 million, growing 5% organically.

CooperSurgical: Comprehensive IVF Cycle Support

In the fertility space, CooperSurgical provides a full suite of products supporting the In Vitro Fertilization (IVF) cycle. This end-to-end support is a key differentiator for clinics.

• Fertility revenues in the fourth quarter were $141 million.
• The company is seeing encouraging traction with new RFP (Request for Proposal) wins from major fertility clinics.
• Genomics portfolio is seeing an uptick in momentum following recent new test launches.

CooperSurgical delivered quarterly revenue of $356 million, up 3.9% organically for the quarter.

CooperSurgical: Paragard, The Non-Hormonal IUD

Paragard is a unique offering in the U.S. contraceptive market, providing a non-hormonal option with extended protection, which is a strong value driver for patients seeking alternatives.

• Paragard grew 16% in the fourth quarter.
• CooperSurgical holds 17% of the U.S. IUD market.
• The U.S. IUD market was projected to reach $1.55 billion in 2025.
• The product offers up to 10 years of protection.

The company is focused on driving growth in this segment, even as guidance for Q1 2026 assumed flat to low single-digit growth for Paragard.

Clinical Credibility and Scientific Leadership

The Cooper Companies, Inc. emphasizes scientific backing over broad advertising spend, which resonates with ECPs and specialists. This is evident in the focus on clinical data for key products.

• Peer-reviewed research validates the retention of myopia control gains with MiSight 1 day lenses.
• The company is focused on operational efficiency and generating strong returns through capital deployment initiatives.
• Non-GAAP operating margin improved by 110 basis points to 27% in Q4 2025, driven by operating expense leverage.

The overall fiscal 2025 non-GAAP diluted EPS was $4.13, up 12% year-over-year.

Finance: draft 13-week cash view by Friday.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Customer Relationships

The Cooper Companies, Inc. (COO) employs a dual-pronged approach to customer relationships, segmenting its engagement based on the distinct needs of its CooperVision (CVI) and CooperSurgical (CSI) customer bases.

Dedicated, high-touch professional engagement with ECPs and fertility specialists.

For CooperVision, the relationship focus involves strengthening branded sales, especially among independent optometrists. This high-touch engagement supports premium products like the MyDay portfolio, which saw strong momentum, and the MiSight product, which was up 37% in Q4 2025. The CVI segment achieved total fiscal year 2025 revenue of $2,743.8 million. For CooperSurgical, customer service is a competitive factor, specifically mentioning response time and effective communication of product information to physicians, fertility clinics, and hospitals. The CSI segment finished fiscal year 2025 with revenue of $1,348.6 million. The relationship-driven model is critical here, as the CSI office and surgical segment saw a 6% growth in Q4 2025, partly driven by sales of Paragard. However, the fertility segment experienced only 1% growth in Q4 2025 due to tight consumer spending in that area.

The Cooper Companies, Inc. maintains a substantial workforce of more than 16,000 employees to support these professional engagements.

Digital self-service via the B2B e-commerce platform, MyCooperVision.

The digital relationship is centered on the MyCooperVision platform, providing customers with 24/7 access for online ordering, checking order status, and shipment tracking. This self-service capability is designed to offer flexibility and low-cost transaction processing. The platform also includes CooperVision® PRO, a patient management solution offered as a free of charge, value-added service. Market trends suggest that 70% of B2B decision-makers prefer making purchases online as of 2025, and 80% of B2B sales interactions happen online. The Cooper Companies, Inc. is also looking to roll out digital fitting and subscription models in North America and Europe to further enhance digital customer interaction.

Long-term contracts with large managed vision care plans and optical chains.

Contractual relationships are a key mechanism for securing volume and market access. CooperVision is building momentum with MyDay contract wins. The company services three primary regions: Americas ($1,124.3 million in net sales in FY2025), EMEA ($1,064.4 million), and Asia Pacific ($555.1 million). The overall CVI segment revenue for fiscal year 2025 was $2,743.8 million. The company is looking to secure multi-year supply agreements within its CooperSurgical division, specifically with IVF chains.

Relationship-driven model, especially for complex CooperSurgical capital equipment.

For CooperSurgical, the model leans heavily on direct relationships, particularly for its more complex offerings. The CSI strategy includes pursuing regulatory approvals and market entries in LATAM, the Middle East, and India through 2025-2026 to capitalize on double-digit IVF cycle growth markets. Furthermore, the company aims to expand laboratory workflow partnerships with analytics-enabled benchtop equipment. The total consolidated revenue for The Cooper Companies, Inc. in fiscal year 2025 reached $4,092.4 million.

The relationship strategy is projected to continue driving growth, with The Cooper Companies, Inc. guiding for fiscal 2026 total revenue between $4,299 million and $4,338 million.

Metric	Segment/Scope	FY 2025 Amount (USD)	Change/Detail
Total Revenue	Consolidated	$4,092.4 million	Up 5% from fiscal 2024
Net Sales	CooperVision (CVI)	$2,743.8 million	Up 5% from fiscal 2024
Net Sales	CooperSurgical (CSI)	$1,348.6 million	Up 5% from fiscal 2024
Q4 2025 Revenue	CooperVision (CVI)	$709.6 million	Up 5% year-over-year
Q4 2025 Revenue	CooperSurgical (CSI)	$355.6 million	Up 4% year-over-year
Product Growth	MiSight Sales (CVI)	N/A	Up 37% in Q4
Product Growth	Toric and multifocal lenses (CVI)	N/A	Grew 7% in FY2025
Segment Growth	CSI Office and surgical segment	N/A	Grew 6% in Q4 2025

The digital engagement tools offered include:

• Access to online ordering for store and patient home delivery.
• Ability to search order history, shipment status, and tracking.
• Reminders of latest key products and policies.
• Access to CooperVision® PRO patient management system.

The Cooper Companies, Inc. is also focused on future relationship enhancements, with plans to roll out digital fitting and subscription models in North America and Europe.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Channels

You're looking at how The Cooper Companies, Inc. gets its products, mainly contact lenses from CooperVision and women's health/surgical products from CooperSurgical, to the end-user. The channel strategy is clearly segmented by product line and geography.

For CooperVision, the primary route is through a vast network of independent eye care professionals (ECPs) and distributors. While the exact percentage for wholesale distributors isn't public, the sheer scale of the business suggests this is the backbone. CooperVision is the number one contact lens company in the world by wearers, serving approximately 43 million people globally.

The direct sales approach is more pronounced in the CooperSurgical segment, targeting hospitals and clinics. Office and surgical net sales for CooperSurgical grew by 6% in fiscal year 2025. This points to a dedicated sales force engaging directly with healthcare facilities for products like Paragard and obp Surgical assets.

The B2B e-commerce platform faces headwinds in certain areas. For instance, in the fourth quarter of fiscal 2025, the China market saw a significant 28% decline, which management attributed to weakness in low-margin e-commerce channels. This shows a clear risk area for that specific channel.

International market penetration is critical, especially in APAC. Looking at the third quarter of fiscal 2025, the Asia Pacific region showed only 1% revenue growth for CooperVision. This contrasts sharply with the EMEA region's 14% growth in the same period, suggesting varying levels of success or different channel mixes, possibly involving exclusive deals, across international markets.

Here's a look at the revenue scale and regional channel performance for the CooperVision segment in fiscal year 2025:

CooperVision Metric	Amount (Fiscal Year 2025)	Source Data Point
Total CooperVision Net Sales	$2,743.8 million	Toric/Multifocal ($1,351.3M) + Sphere/Other ($1,392.5M)
Toric and Multifocal Lenses Net Sales	$1,351.3 million	Primary driver: Biofinity and MyDay success
Sphere, Other Lenses Net Sales	$1,392.5 million	Primary driver: MiSight and MyDay success
Total Consolidated Revenue	$4.09 billion	Full Year Fiscal 2025 Revenue

The reliance on ECPs and distributors is evident in the regional breakdown, where the Americas and EMEA drive the bulk of the business:

• EMEA CooperVision revenue growth (Q3 2025): 14%
• Americas CooperVision revenue growth (Q3 2025): 2%
• Asia Pacific CooperVision revenue growth (Q3 2025): 1%
• CooperVision Q4 2025 Revenue: $710 million
• FY 2026 CooperVision Revenue Guidance: $2.9 billion to $2.925 billion

For the CooperSurgical segment, direct engagement with facilities is key, as shown by the growth in office and surgical sales:

• CooperSurgical Office and Surgical Net Sales Growth (FY 2025): 6%
• CooperSurgical FY 2026 Revenue Guidance: $1.4 billion to $1.413 billion

Finance: draft 13-week cash view by Friday.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Customer Segments

You're looking at how The Cooper Companies, Inc. (COO) carves up its market, which is really two distinct worlds: vision care and women's health. It's a dual approach, but the customer focus within each division is razor-sharp.

For CooperVision, the customer base is split between the professionals who fit the lenses and the people who wear them. On the professional side, we see a heavy concentration of volume. Honestly, the top 20% of Eye Care Professionals (ECPs) account for an estimated 60% of contact lens volume. This means a small group of high-value partners drives a huge chunk of the business.

The end-consumer focus for CooperVision is clearly defined by age and need. The core demographic is generally adults between 25-54 years old who have mid-to-high disposable income. But, a critical growth area is the 45+ presbyopia demographic, which represents over 25% of the global population. These are the folks needing multifocal correction, and The Cooper Companies, Inc. (COO) is actively targeting them with products like MyDay multifocal lenses.

Switching gears to CooperSurgical, this division is overwhelmingly Business-to-Business (B2B). They serve specific healthcare providers, which include fertility clinics, hospital systems, and OB/GYN practices. The fertility segment has been a key driver, showing over 12% year-over-year growth as of 2024.

The overall reach of The Cooper Companies, Inc. (COO) is global, serving a vast patient base needing specialized vision correction and women's healthcare solutions. As of August 2025, the company sells products in over 130 countries and impacts more than fifty million lives annually.

Here's a quick look at the revenue contribution from these segments in the fourth quarter of fiscal 2025, just to ground the discussion in recent numbers:

Segment	Q4 Fiscal 2025 Revenue	Year-over-Year Growth (Reported)
CooperVision (CVI)	$709.6 million	5%
CooperSurgical (CSI)	$355.6 million	4%

The CooperVision segment is clearly the larger revenue generator, but CooperSurgical's fertility business is noted for its strong growth trajectory.

To summarize the professional targets for CooperVision, you're looking at a highly engaged group of prescribers:

• Eye Care Professionals (ECPs) as the primary B2B channel.
• High-value ECPs driving an estimated 60% of contact lens volume.
• Providers of fertility services and women's health procedures for CooperSurgical.

The end-user base is defined by specific needs, too. For CooperVision, it's about vision correction for the working-age adult and the aging population needing presbyopia solutions. For CooperSurgical, it's patients utilizing fertility services or requiring office/surgical devices like Paragard.

Finance: draft 13-week cash view by Friday.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Cost Structure

You're looking at the expenses The Cooper Companies, Inc. (COO) is managing to deliver its products, and it's clear that manufacturing and selling are the big drivers of cost. Here's a breakdown of the key components based on the late 2025 financials.

High Cost of Goods Sold and Gross Margin Pressure

The nature of manufacturing contact lenses and surgical devices means the Cost of Goods Sold (COGS) is inherently high. For the full fiscal year 2025, The Cooper Companies, Inc. reported a GAAP gross margin of 66%. However, the fourth quarter showed some immediate pressure points. The GAAP gross margin for Q4 2025 specifically dropped to 61%, down from 67% in the prior year's fourth quarter, largely due to costs tied to reorganization activity. On a non-GAAP basis, the Q4 2025 gross margin was 66%, a 70 basis point decline from the prior year, which management attributed primarily to tariffs and product mix pressures. This shows the sensitivity of the core cost structure to external factors and internal restructuring.

Here's a quick look at those Q4 2025 margin figures:

Metric	Q4 2025 GAAP	Q4 2025 Non-GAAP
Gross Margin	61%	66%
Operating Margin	13%	27%

Research & Development Commitment

The Cooper Companies, Inc. maintains a commitment to innovation, which requires consistent R&D spending to support product launches like those in the CooperVision segment. While the specific R&D expense for Q4 2025 wasn't detailed in the summary results, management indicated that for fiscal 2026, there are no significant reductions in R&D investments planned. This suggests R&D remains a necessary, ongoing cost to fuel future growth, especially with new product rollouts expected.

Selling, General, and Administrative (SGA) Expenses

The global sales force supporting both CooperVision and CooperSurgical necessitates substantial SGA costs. For the fourth quarter of 2025, the company reported that operating expenses were flat, which management attributed to disciplined cost management. Furthermore, executives stated that no significant reductions in SG&A are planned moving into fiscal 2026, implying this cost base is considered necessary for current operations and market reach.

Restructuring, Tariffs, and Mix Costs

The immediate impact of the Q4 2025 reorganization activity was visible in the GAAP margin compression. To offset these costs and drive future efficiency, the company expects the ongoing reorganization efforts to generate $50 million in annual pre-tax savings starting in fiscal 2026. This is a direct cost management action taken to counteract the impact of tariffs and adverse product mix that pressured the non-GAAP gross margin.

Financing Costs

The balance sheet carries significant debt obligations that result in regular interest expense. The total debt at the end of fiscal Q4 2025 stood at $2.51 billion. This debt level resulted in a Q4 2025 interest expense of $23.7 million on a non-GAAP basis, a reduction from the prior year driven by lower average interest rates and a lower average debt balance.

You should track the realization of those expected reorganization savings, as that will be key to margin recovery.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Revenue Streams

The revenue streams for The Cooper Companies, Inc. are clearly segmented across its two primary divisions: CooperVision (CVI) and CooperSurgical (CSI). For the fiscal year ended October 31, 2025, the total company revenue reached $4,092.4 million.

The contact lens segment, CooperVision, remains the larger contributor to the top line, while CooperSurgical provides a significant, high-growth complement in women's healthcare and fertility. You can see the breakdown of the total fiscal year 2025 revenue here:

Revenue Stream Segment	FY2025 Revenue Amount
Total Company Revenue	$4,092.4 million
Contact Lens Sales (CooperVision)	$2,743.8 million
Women's Healthcare & Fertility Sales (CooperSurgical)	$1,348.6 million

Within these segments, the focus is heavily on premium, high-margin products that drive both initial sales and recurring revenue. This strategy is key to maintaining margin health, even with external pressures like tariffs.

The CooperVision business relies on the ongoing adoption of advanced lens technologies. This is where the recurring revenue from consumables really takes hold:

• Sales of premium, high-margin products like MyDay contact lenses, which saw double-digit revenue growth in the third quarter of fiscal 2025.
• The myopia management portfolio, highlighted by MiSight lenses, which grew revenue by 23% in the third quarter of fiscal 2025.
• Daily silicone hydrogel lenses, a core component of the recurring revenue stream, grew 10% in the second quarter of fiscal 2025.

For CooperSurgical, the revenue stream is diversified across surgical devices and fertility solutions. The fertility business, which provides a recurring element through media and ongoing patient support, is a notable growth driver:

• Fertility revenues specifically totaled $137 million in the third quarter of fiscal 2025, marking a 6% increase year-over-year.
• The overall CooperSurgical segment contributed $1,348.6 million to the total fiscal 2025 revenue.

The company is actively managing its product mix to favor these higher-value items. Finance: draft 13-week cash view by Friday.